Author Guidelines for British Journal of Pharmacology

[Pages:26]Author Guidelines for British Journal of Pharmacology

Useful links Author Guidelines: PDF Ethics Policy Submission website BJP Policy Editorials Approved Abbreviations List Declaration of Transparency and Scientific Rigour: CHECKLISTS How to Link to the Guide to Pharmacology

Sections

1. Submission 2. Aims and Scope 3. Manuscript Categories and Requirements 4. Preparing the Submission 5. Editorial Policies and Ethical Considerations 6. Author Licensing 7. Publication Process After Acceptance 8. Post Publication 9. Editorial Office Contact Details 10. Transfer to other British Pharmacological Society (BPS) Journals

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. The journal will accept submissions where the experimental protocol has been pre-registered and/or published elsewhere.

Free format submission BJP now offers free format submission for a simplified and streamlined submission process.

Before you submit, you will need:

? Your manuscript: this can be a single file including text, figures, and tables, or separate files ? whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers. If your manuscript is difficult to read, the editorial office may send it back to you for revision.

? The title page of the manuscript, including statements relating to our ethics and integrity policies: - data availability statement - funding statement - author contribution statement - conflict of interest disclosure - ethics approval statement - permission to reproduce material from other sources.

? Your co-author details, including affiliation and email address.

? An ORCID ID, freely available at . The submission system will prompt corresponding authors to use an ORCID iD (a unique author identifier) to help distinguish their work from that of other researchers. Click here to find out more.

To submit, login at and create a new submission. Follow the submission steps as required and submit the manuscript. Click here for more details on how to use ScholarOne. For help with submissions, please contact BJPedoffice@.

If you are invited to revise your manuscript after peer review, the journal will also request the revised manuscript to be formatted according to journal requirements as described below.

Article Preparation Support Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design ? so you can submit your manuscript with confidence. Also, please see Preparing the Submission, below, for general guidance on writing and preparing your manuscript.

Preprint policy Please find the Wiley preprint policy here. This journal accepts articles previously published on preprint servers. BJP will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.

Preprint your manuscript while it's under review Beginning in early 2020, British Journal of Pharmacology is participating in the pilot of the under review service, Wiley's new initiative to streamline the early sharing of research and open up the peer review process. Authors can now opt to preprint their manuscript during the submission process and showcase their work to the global research community as a preprint, before it is accepted or published. The under review service is powered by Authorea, an open research platform for all your research outputs, including data, figures, and preprints. By opting-in authors can:

? Seamlessly preprint at the same time you submit your research for publication ? Share your work early, while indicating it is being considered at a specific journal ? Track the peer review process openly in real time ? Immediately make their work citable, discoverable, and easily shareable ? Get additional community feedback that can be used to improve your manuscript

Learn more about the benefits of the under review service.

Fast-track Review Service When research articles are of exceptional importance and urgency, we can offer a fast-track review service with a first decision within 10 calendar days from invitation. Authors must provide a strong scientific rationale (in an argument of no more than 500 words) for why BJP should consider their article under this expedited service. The Editor-In-Chief, with the Senior Editorial Board members, will decide whether fast-track review is warranted and if so approve the article for the service. The fast-track service is available only when there is clear urgency in terms of relevancy for the community, for example during a worldwide pandemic, or when there is significant competition to publish in that area. Authors must provide a clear rationale for why their article should be considered as a fast track submission. Papers will not be entered into the fast-track service for personal reasons, such as meeting an institutional deadline.

2. AIMS AND SCOPE

The British Journal of Pharmacology is a broad-remit journal giving leading international coverage of all aspects of experimental pharmacology. The journal publishes high-quality original research, authoritative reviews, mini reviews, letters to the Editor and commentaries. Review articles are normally commissioned, but consideration will be given to unsolicited contributions. Reviews can be standalone or part of a themed issue. BJP also publishes the Concise Guide to Pharmacology, which is a snapshot in time of the BPS/IUPHAR Guide to Pharmacology database and published biennially. Commentaries are invited by the Editor-in-Chief on articles published in the journal. Letters to the Editor are acceptable where they are a comment on a paper published in the journal or relate to current issues pertinent to the field of pharmacology. BJP publishes translational pharmacology research which includes proof-of-concept and early mechanistic studies in humans. BJP does not generally publish first in man phase I for new molecular entities, phase IIb, III or IV studies. BJP does not publish work on the actions of biological extracts of unknown chemical composition (e.g. unpurified and unvalidated) or unknown concentration. Papers that involve investigations on tobacco, smoking, alcohol, cocaine and other substances of abuse, whether directly or in the context of their use to generate a disease model (e.g. smoking for pulmonary disease), will be considered on scientific merit (which includes ethical justification) and relevance to pharmacology.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Minimise the use of abbreviations throughout your manuscript. BJP has an Approved Abbreviations List, which you should use where possible; for abbreviations not on this list, please define on first use. Please keep non-approved abbreviations to a minimum.

? i. Research Papers

Description: The scope should be pharmacological, i.e. focus on drugs and/or drug targets by characterising novel effects or mechanisms, or by validating new analytical approaches, methods or models and must constitute a significant contribution to pharmacological knowledge. BJP welcomes translational and systems pharmacology approaches to drug discovery and validation. Papers that reassess pharmacological concepts based on earlier results, and purely theoretical papers, will be considered. Papers describing new methods in pharmacology that embody new principles are also welcome. We encourage publication of replication studies on issues of major importance to pharmacology where there is considerable

uncertainty, subject to the discretion of the senior editorial board. Word limit: 4,000 words, excluding abstract, Methods, references and figure legends. Abstract: 250 words; must be structured, under the following sub-headings: Background and Purpose, Experimental Approach, Key Results, Conclusion and Implications. Minimise abbreviations and do not include any references. Methods: Should be fully transparent with sufficient detail to enable replication by others. There is no word limit. Discussion and Conclusions: 1,500 words. References: Ideally, no more than 60 references, with a focus on primary publications. Title: 160 characters (including spaces). Keywords: Supply between 3 and 7. Figures/Tables: Total of no more than 10 figures and tables (excluding supporting files). Bullet point summary: Supply three bulleted sections, entitled `What is already known', `What this study adds' and ` Clinical significance', in this order. Each heading must have at least one bullet point, but no more than two. Each bullet point should have a maximum of 15 words.

? ii. Review Articles

Description: Reviews are comprehensive analyses of the pharmacological literature. Authors of unsolicited reviews must submit them directly to ScholarOne, following the standard submission procedure. Word limit: 6,000-8,000 words excluding abstract, references and figure legends. (Please cite word count on your manuscript). Title: Up to 160 characters (including spaces). Abstract: Up to 150 words; must be non-structured. References: Up to 150 references. Structure: Authors should break up their reviews into headed sections. Figures/Tables: There should be a minimum of two figures one of which should illustrate the major findings/pathways discussed. There should be a total of no more than 5 figures and tables (combined). The use of explanatory figures in the form of cartoons, flow diagrams, etc., is encouraged. Professional assistance can be provided ? please contact the editorial office. Abbreviations: Use the approved abbreviations list.

? iii. Invited Minireviews

Description: Focus on hot and emerging topics, commissioned only. Word limit: 2,000 words, excluding abstract, references and figure legends. Abstract: Up to 150 words, unstructured. References: Up to 30. Figures: No more than two (one of which should summarise the major findings discussed). Tables: No more than one Titles: Up to 85 characters.

? iv. Hypotheses

Description: A hypothesis paper should act as a stimulant for debate of new pharmacological research advancing understanding of mechanisms of drug action. These articles will normally discuss controversial topics, potentially offer new insight to an old problem or a current issue. These articles must not include any unpublished or original data. Importantly, the proposal must be supported by evidence and thus be fully referenced. We also encourage authors to provide a figure summarising the potential novel mechanism/pathway being proposed. Word limit: 1,600-2,000 words, excluding abstract, references and figure legends. Abstract: Up to 150 words; unstructured. References: Up to 20. Figures: One summary figure. Tables: None.

? v. Invited Commentaries

Description: Commentaries on BJP published research are invited only. They should contain no new or unreviewed data. Word limit: 1,200 words, excluding references. Abstract: There should be no abstract, no structuring. References: Maximum of 5 references. Figures/Tables: None

? vi. Letters to the Editor

Description: Letters should contain no new or unreviewed data. Any correspondence is limited to specific comments or responses relating to a recent BJP paper and current issues of importance to pharmacology. Where the letter relates to a recent BJP paper the authors will be invited to reply. Word limit: 800 words, excluding references. Abstract: No abstract. References: Up to 5 references. Figures/Tables: None.

4. PREPARING THE SUBMISSION

Manuscript Preparation in Detail - Research Papers

Abstract

The abstract must be structured, under the following sub-headings: Background and Purpose: This must indicate why the study was performed and what question it was intended to answer. Experimental Approach: This should state in outline what experimental methods were used. Details on media, buffers, drug concentrations, time points, statistics, etc., should not be given unless they are important in relation to the question that was addressed. Key Results: The main results relevant to the question addressed should be summarised without quantitative elaboration (for example, `Drug X increased coronary blood flow by 25%, whereas drug Y had no effect', rather than `Coronary blood flow after drug [RA1] X (10 ?mol min-1 i.v. for 15 minutes) was increased from 19.4?3.2 ml min-1 (means ? sem n = 6) to 26.2?4.1 ml min-1 (n=6). The effect was statistically significant (p ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download